biote beats on profit but misses on sales

BTMD reported Q1 2026 earnings on May 6 with a story that cuts both ways — a bottom-line beat paired with a top-line miss, arriving into a stock that has already rallied 39% over the past month.

The numbers landed with a split verdict. EPS came in at $0.06, doubling the $0.03 consensus estimate. Revenue, however, fell short at $44.9 million against expectations of $46.0 million. That miss extends a pattern from Q4 2025, when procedure revenue dropped 13% year-on-year. The core drag is the same: net new clinic additions remain below the pace needed to offset attrition and grow the top line. Management acknowledged this on the Q4 call, flagging a planned expansion of the sales force from roughly 90 to approximately 120 heads through 2026 — an investment that will weigh on adjusted EBITDA even as it is meant to reverse the growth trend.

Short sellers have been quietly rebuilding exposure into the print. SI % of free float moved from roughly 7.5% at the end of March to 8.6% by May 5 — a steady six-week grind higher. That build is meaningful for a stock this small ($71 million market cap), representing genuine conviction rather than rounding noise. The one-month increase in short shares is around 13%. Notably, the borrow market remains relaxed. Availability is running at nearly 400% of current short interest — meaning shares to lend are plentiful relative to what has already been borrowed. Cost to borrow is sub-1%, down around 15% on the week. That combination — rising SI in a loose lending market — suggests shorts are adding at low friction, not fighting a squeeze.

The analyst picture is one of downward revision without capitulation. Truist Securities, the most recent mover (April 16), cut its target from $5.00 to $4.00 while holding a Buy rating. Prior to that, TD Cowen and B. Riley both trimmed targets to the $2.00–$2.50 range in March following the Q4 miss, with B. Riley holding Neutral. The mean target across the coverage group is roughly $2.97, a 35% premium to Tuesday's close of $2.21. That gap looks generous given the revenue trajectory. Valuation multiples offer a more nuanced read: the EV/EBITDA multiple is 3.9x, and the trailing PE is a modest 4.4x — both reflecting the market's scepticism about whether the profit-quality story holds as investment spending ramps. The factor score for EV/EBIT ranks in the 88th percentile, suggesting the stock screens as cheap on an earnings basis relative to the broader universe.

The short score has been oscillating in a tight band around 60 all month, touching a recent high of 61.9 on April 22 before easing slightly to 60.2 by May 5. The score ticked up two points on the day earnings were released — a modest uptick consistent with the mixed result rather than a directional signal. The one prior earnings reaction in the dataset is telling: after Q4 2024 results in March 2026, the stock fell 9.4% on the day and 20% over the following five sessions. That reaction followed a revenue miss and a downbeat guide. Q1 2026 delivered another revenue miss, though the EPS beat was sharper this time.

The key thing to watch after this print is whether the May revenue run-rate and new practitioner training pipeline — cited by CEO Bret Christensen as a leading indicator — show any sequential improvement when management next updates the market. The earnings call transcript reveals all training sessions were at full capacity from mid-November onward. Whether that converts into procedure revenue growth, or remains another near-term hope deferred, is the number shorts and bulls alike are waiting to see.